The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.
Several factors, including body mass index (BMI), diabetes mellitus, and age, are associated with the risk of progression from prehypertension to hypertension among middle-aged and elderly adults, according to a 12-year Korean cohort study.
More than two-thirds of Asian patients with ischaemic diabetic heel ulcers survived without requiring an amputation at 1 year following lower limb revascularization surgery — a rate better than previously reported in the literature, according to a local study.
Patients with multivessel coronary artery disease (CAD) and diabetes treated with coronary artery bypass grafting (CABG) have improved long-term mortality and freedom from major cardiovascular and cerebrovascular events (MACCEs) compared to those treated with percutaneous coronary intervention (PCI), according to a study.
Metformin use in patients with type 2 diabetes (T2D) appears to contribute to an early reduction in haemoglobin levels, which in turn leads to a higher incidence of moderate anaemia, according to data from the MASTERMIND study.
Individuals with obesity are likely to maintain a healthy metabolic status on a vegetarian or vegan diet, according to a study. But simply adhering to this dietary pattern does not assure better outcome, because some plant-based foods are less nutritious.
In patients with type 1 diabetes (T1D) without known heart disease, cardiac time intervals positively correlate with major adverse cardiovascular events (MACE), according to a study presented at the ESC Congress 2020: The Digital Experience.
Patients with type 2 diabetes (T2D) who initiated SGLT2* inhibitors (SGLT2is) had better cardiovascular (CV) outcomes than those on DPP-4** inhibitors, shows the large, global, real-world study, CVD-REAL 2.
In the treatment of patients with type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD), the first-in-class GLP-1/glucagon dual-receptor agonist cotadutide confers positive effects on body weight, alanine aminotransferase levels, and markers of liver fat and fibrosis, although these benefits appear to come with adverse gastrointestinal events, as shown in a phase IIb study.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.